4.5 Article

Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza

Journal

VACCINE
Volume 28, Issue 37, Pages 5952-5959

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.07.003

Keywords

Influenza; Workplace; Vaccination

Funding

  1. National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109]
  2. National Library of Medicine (NLM) [5R01LM009132-02]
  3. Centers for Disease Control and Prevention (CDC) [1P01HK000086-01]

Ask authors/readers for more resources

Employers may be loath to fund vaccination programs without understanding the economic consequences. We developed a decision analytic computational simulation model including dynamic transmission elements that estimated the cost-benefit of employer-sponsored workplace vaccination from the employer's perspective. Implementing such programs was relatively inexpensive (<$35/vaccinated employee) and, in many cases, cost saving across diverse occupational groups in all seasonal influenza scenarios. Such programs were cost-saving for a 20% serologic attack rate pandemic scenario (range: -$15 to -$995) per vaccinated employee) and a 30% serologic attack rate pandemic scenario (range: -$39 to -$1,494 per vaccinated employee) across all age and major occupational groups. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available